Impact of timing of midazolam administration on incidence of postoperative nausea and vomiting in patients undergoing laparoscopic gynecological surgery: A randomized, double-blinded, controlled study
Egyptian journal of Anaesthesia • 2022
Publication Information
Authors
Samar Rafik Amin, Taghreed Elshahat Sakr & Shaimaa Ezzat Amin
Keywords
Postoperative nausea and
vomiting; midazolam;
antiemetics; laparoscopy
Journal
Egyptian journal of Anaesthesia
Publisher
Taylor and Francis
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
International
Paper Link
Open Link
Supplementary Materials
Not Available
Abstract
Background: A frequently used anxiolytic, midazolam, has recently been recognized for its
antiemetic activity during the perioperative period. This study sought to investigate the best
time to provide midazolam in order to decrease the frequency of postoperative nausea and
vomiting (PONV) without increasing the risk of sedation.
Methods: A total of 120 women aged 20–60 years who underwent laparoscopic gynecological
surgeries were distributed randomly to three groups: group M1 (n = 40) received intravenous
2 mg midazolam 15 min prior anesthesia induction, group M2 (n = 40) received intravenous
2 mg midazolam approximately 30 min prior surgery conclusion, and group C (n = 40) received
intravenous normal saline. The frequency of PONV and the rescue antiemetics needs were
measured as the primary outcomes during the first 24 hr postoperatively. The secondary
outcomes were the severity of nausea, timing of initial emetic attack, time of PACU discharge,
patient sedation, and pain scores.
Results: The frequencies of vomiting and rescue antiemetic use were lower in midazolam
groups than controls during early (0–2) and late (0–24) time periods after surgery (P < 0.05),
with insignificant difference between M1 and M2 groups. The timing of the first emetic episode
was significantly longer in M2 than in C groups (458.3 vs 128.8 minutes) (P < 0.01). Insignificant
differences with regard to frequency and severity of nausea, time of PACU discharge, and
sedation score were detected among the three groups.
Conclusion: Midazolam was effective in reducing PONV, whether it was given prior induction
of anesthesia or prior end of surgery, without influencing recovery duration or sedation level of
the patients.
antiemetic activity during the perioperative period. This study sought to investigate the best
time to provide midazolam in order to decrease the frequency of postoperative nausea and
vomiting (PONV) without increasing the risk of sedation.
Methods: A total of 120 women aged 20–60 years who underwent laparoscopic gynecological
surgeries were distributed randomly to three groups: group M1 (n = 40) received intravenous
2 mg midazolam 15 min prior anesthesia induction, group M2 (n = 40) received intravenous
2 mg midazolam approximately 30 min prior surgery conclusion, and group C (n = 40) received
intravenous normal saline. The frequency of PONV and the rescue antiemetics needs were
measured as the primary outcomes during the first 24 hr postoperatively. The secondary
outcomes were the severity of nausea, timing of initial emetic attack, time of PACU discharge,
patient sedation, and pain scores.
Results: The frequencies of vomiting and rescue antiemetic use were lower in midazolam
groups than controls during early (0–2) and late (0–24) time periods after surgery (P < 0.05),
with insignificant difference between M1 and M2 groups. The timing of the first emetic episode
was significantly longer in M2 than in C groups (458.3 vs 128.8 minutes) (P < 0.01). Insignificant
differences with regard to frequency and severity of nausea, time of PACU discharge, and
sedation score were detected among the three groups.
Conclusion: Midazolam was effective in reducing PONV, whether it was given prior induction
of anesthesia or prior end of surgery, without influencing recovery duration or sedation level of
the patients.
Staff Members - Benha University